Department of Clinical Microbiology and Immunology, School of Medicine, Tel Aviv University, Tel Aviv, Israel.
RNA Biol. 2023 Jan;20(1):830-835. doi: 10.1080/15476286.2023.2270344. Epub 2023 Oct 16.
Most recently developed phage engineering technologies are based on the CRISPR-Cas system. Here, we present a non-CRISPR-based method for genetically engineering the phages T5, T7, P1, and λ by adapting the pORTMAGE technology, which was developed for engineering bacterial genomes. The technology comprises harbouring a plasmid encoding a potent recombinase and a gene transiently silencing a repair system. Oligonucleotides with the desired phage mutation are electroporated into followed by infection of the target bacteriophage. The high efficiency of this technology, which yields 1-14% of desired recombinants, allows low-throughput screening for the desired mutant. We have demonstrated the use of this technology for single-base substitutions, for deletions of 50-201 bases, for insertions of 20 bases, and for four different phages. The technology may also be readily modified for use across many additional bacterial and phage strains.[Figure: see text].
最近开发的噬菌体工程技术基于 CRISPR-Cas 系统。在这里,我们提出了一种非基于 CRISPR 的方法,通过适应 pORTMAGE 技术来遗传工程改造噬菌体 T5、T7、P1 和 λ,该技术最初是为工程化细菌基因组而开发的。该技术包括携带编码强效重组酶的质粒和瞬时沉默修复系统的基因。用带有所需噬菌体突变的寡核苷酸进行电穿孔,然后感染目标噬菌体。这种技术的高效率(产生 1-14%的所需重组体)允许对所需突变体进行低通量筛选。我们已经证明了该技术在单碱基替换、50-201 个碱基的缺失、20 个碱基的插入以及四种不同噬菌体中的应用。该技术也可以很容易地修改,以用于许多其他细菌和噬菌体菌株。[图:见正文]。